Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
May 10 2021 - 7:30AM
Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, including multiple
oncology product candidates and a novel COVID-19 vaccine, today
announced the appointment of Anthony Manning, Ph.D. as Chief
Scientific Advisor. Dr. Manning will be responsible for strategic
initiatives to accelerate the development of Heat Biologics’
product portfolio.
Dr. Manning brings over three decades of
experience in immunology and autoimmune disease research and
development. Most recently, Dr. Manning served as Chief Scientific
Officer and Head of Research at Momenta Pharmaceuticals, a
biotechnology company focused on biologic therapeutics to treat
rare immune-mediated diseases. At Momenta, Dr. Manning provided
strategic leadership to all research activities, including the
discovery and development of three novel autoimmune drug
candidates. Momenta was recently acquired by Johnson & Johnson
for approximately $6.5 billion. Prior to Momenta, Dr. Manning
served as Senior Vice President of Research and Preclinical
Development at Aileron Therapeutics, where he oversaw target
selection, lead identification and optimization, clinical candidate
selection, and IND-enabling studies. Before Aileron, Dr. Manning
served as Vice President and Head of Inflammation and Autoimmune
Disease Research at Biogen, and previously served as Vice President
and Global Therapy Area Head of Inflammation, Autoimmunity &
Transplantation Research at Roche. Dr. Manning is a member of the
Board Directors of Palatin Technologies, Inc, Chairman of the
Institute for Biomedical Entrepreneurship, and an Advisor to the
Harvard Medical School Therapeutics Initiative. He is an author and
inventor on over 120 publications and patents relating to
autoimmune disease and novel drug discovery.
Jeff Wolf, Chief Executive Officer of Heat
Biologics, commented, “We are thrilled to welcome Dr. Manning to
our team. With his proven track record in the drug discovery,
research and development, Dr. Manning will provide strategic
leadership and invaluable insight to accelerate the development of
our portfolio programs. ”
“I am excited to be joining Jeff and the team at
Heat Biologics,” stated Dr. Manning. “My entire professional career
has been aimed at targeting the immune system and Heat’s
first-in-class pipeline holds immense promise for improving current
standard of care. I look forward to working with the team to expand
and advance the innovative pipeline programs.”
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in its Phase 2 trial, and a COVID-19
vaccine program in preclinical development. In addition, Heat
Biologics is also developing a pipeline of proprietary
immunomodulatory antibodies and cell-based therapies, including
PTX-35 and HS-130 in Phase 1 clinical trials.
Forward Looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectation, and assumptions and include
statements such as Dr. Manning offering invaluable insight as
Heat advances its product pipeline.. These statements are
subject to a number of risks and uncertainties, many of which are
difficult to predict, including the contributions of Dr. Manning to
Heat, the ability of Heat's therapies to perform as designed, to
demonstrate safety and efficacy, as well as results that are
consistent with prior results, Heat's vaccine platform to provide
protection against COVID-19, the ability to enroll patients and
complete the clinical trials on time and achieve desired results
and benefits, especially in light of COVID-19, Heat's ability to
obtain regulatory approvals for commercialization of product
candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to Heat's ability to promote or
commercialize its product candidates for specific indications,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, Heat's
ability to maintain its license agreements, the continued
maintenance and growth of its patent estate, its ability to
establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities, its ability to continue to maintain its
listing on the Nasdaq Capital Market and its ability to retain its
key scientists or management personnel, and the other factors
described in Heat's most recent annual report on Form 10-K filed
with the SEC, and other subsequent filings with the SEC. The
information in this release is provided only as of the date of this
release, and Heat undertakes no obligation to update any
forward-looking statements contained in this release based on new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heat Biologics (NASDAQ:HTBX)
Historical Stock Chart
From Sep 2023 to Sep 2024